CAPMATINIB for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 22 adverse event reports in the FDA FAERS database where CAPMATINIB was used for Neoplasm malignant.
Most Reported Side Effects for CAPMATINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 411 | 17.9% | 410 | 23 |
| Peripheral swelling | 283 | 12.3% | 10 | 34 |
| Fatigue | 257 | 11.2% | 16 | 40 |
| Oedema peripheral | 247 | 10.7% | 25 | 43 |
| Nausea | 240 | 10.4% | 28 | 56 |
| Malignant neoplasm progression | 178 | 7.7% | 79 | 42 |
| Dyspnoea | 141 | 6.1% | 24 | 51 |
| Oedema | 130 | 5.7% | 12 | 17 |
| Asthenia | 113 | 4.9% | 15 | 30 |
| Non-small cell lung cancer | 96 | 4.2% | 37 | 21 |
| Decreased appetite | 95 | 4.1% | 16 | 30 |
| Joint swelling | 92 | 4.0% | 1 | 8 |
| Vomiting | 83 | 3.6% | 11 | 22 |
| Dysphagia | 80 | 3.5% | 11 | 5 |
| Product dose omission issue | 76 | 3.3% | 5 | 15 |
Other Indications for CAPMATINIB
Product used for unknown indication (838)
Non-small cell lung cancer (543)
Lung neoplasm malignant (420)
Non-small cell lung cancer metastatic (104)
Lung carcinoma cell type unspecified stage 0 (58)
Lung adenocarcinoma (39)
Non-small cell lung cancer stage iv (31)
Lung cancer metastatic (20)
Non-small cell lung cancer recurrent (12)
Lung adenocarcinoma stage iv (11)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)